Sodium metatungstate (hydrate)

Sodium metatungstate (Sodium polyoxotungstate; POM-1) hydrate is a NTPDase inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1 (CD39), NTPDase 3 and NTPDase 2 respectively[1]. Sodium metatungstate has anti-inflammatory and anti-cancer effect. Sodium metatungstate inhibits ATP breakdown but also blocks central synaptic transmission[1][2][3][4].

[Na+].O=[W+4]1234[O-2][W+4]567(=O)[O-2][W+4]89%10(=O)[O-2][W+4]%11%12(=O)([O-2]1)[O-2][W+4]%13(=O)([O-2]8)([O-2][W+4]%14%15%16(=O)[O-2][W+4]%17(=O)([O-2]2)([O-2]%11)[O-2][W+4]%18(=O)([O-2][W+4](=O)([O-2]3)([O-2]5)([O-2][W+4]%19%20(=O)([O-2][W+4]%21(=O)([O

[1]Wall M J, et al. The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition [J]. Neuropharmacology, 2008, 55(7): 1251-1258.|[2]Pimenta-dos-Reis G, et al. POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages [J]. Purinergic Signalling, 2017, 13: 611-627.|[3]Csóka B, et al. CD39 improves survival in microbial sepsis by attenuating systemic inflammation [J]. The FASEB Journal, 2015, 29(1): 25.|[4]Yang R, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade [J]. Journal for immunotherapy of cancer, 2020, 8(1).